We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 22, 2022

The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure

Critical Care Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

Critical Care Medicine
The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial
Crit. Care Med. 2022 Aug 31;[EPub Ahead of Print], JG Youssef, P Lavin, DA Schoenfeld, RA Lee, R Lenhardt, DJ Park, JP Fernandez, ML Morganroth, JC Javitt, D Jayaweera

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading